Melanoma

Vaccine Improves Five-Year Survival Rates

Published in Vaccine Weekly, August 22nd, 2001

CancerVax Corporation announced its intent to prepare a New Drug Submission (NDS) to seek marketing approval in Canada for Canvaxin^TM, a therapeutic vaccine for the treatment of advanced-stage melanoma.

The decision is based on discussions with representatives from the Biologics and Genetic Therapies Directorate of Health Canada's Health Products and Food Branch (Directorate) following the presentation of a summary of Phase II trial results. CancerVax anticipates completing the submission by the third quarter of 2002.

CancerVax presented a summary of the extensive Phase II data on the use of its therapeutic vaccine in patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry